http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 26 May 2026 08:03:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Genprex%2C+Inc.+++++++++++++For%3A+May+26/26546292.html si-local-file:///var/storage/secattach/20260526/26546292.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Genprex%2C+Inc.+++++++++++++For%3A+May+26/26546292.html Tue, 26 May 2026 08:03:00 -0400 GNPX O.21974237 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Genprex%2C+Inc.+++++++++++++For%3A+May+26/26546292.html si-local-file:///var/storage/secattach/20260526/26546292.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Genprex%2C+Inc.+++++++++++++For%3A+May+26/26546292.html Tue, 26 May 2026 08:03:00 -0400 GNPX O.21974237 http://www.streetinsider.com/Corporate+News/Genprex+presents+biomarker+data+for+lung+cancer+gene+therapy+at+ASCO/26546246.html <p>Genprex Inc. (NASDAQ: GNPX) announced that research collaborators published an abstract at the 2026 American Society of Clinical Oncology Annual Meeting detailing biomarker data for its gene therapy candidate Reqorsa in lung cancer patients.</p><p>The study analyzed tumor tissue from 18 patients across three clinical trials testing quaratusugene ozeplasmid. In non-small cell lung cancer patients, those with Trop-2 H-scores above 100 showed prolonged progression-free survival (p=0.05), while PTEN H-scores below 100 also correlated with longer progression-free survival (p=0.03).</p><p>The analysis included six non-small cell lung cancer patients from the Acclaim-1 trial combining the therapy with osimertinib, one patient from Acclaim-2 with pembrolizumab, http://www.streetinsider.com/Corporate+News/Genprex+presents+biomarker+data+for+lung+cancer+gene+therapy+at+ASCO/26546246.html Tue, 26 May 2026 08:01:36 -0400 GNPX http://www.streetinsider.com/FDA/Genprex+presents+biomarker+data+for+lung+cancer+gene+therapy+at+ASCO/26546246.html <p>Genprex Inc. (NASDAQ: GNPX) announced that research collaborators published an abstract at the 2026 American Society of Clinical Oncology Annual Meeting detailing biomarker data for its gene therapy candidate Reqorsa in lung cancer patients.</p><p>The study analyzed tumor tissue from 18 patients across three clinical trials testing quaratusugene ozeplasmid. In non-small cell lung cancer patients, those with Trop-2 H-scores above 100 showed prolonged progression-free survival (p=0.05), while PTEN H-scores below 100 also correlated with longer progression-free survival (p=0.03).</p><p>The analysis included six non-small cell lung cancer patients from the Acclaim-1 trial combining the therapy with osimertinib, one patient from Acclaim-2 with pembrolizumab, http://www.streetinsider.com/FDA/Genprex+presents+biomarker+data+for+lung+cancer+gene+therapy+at+ASCO/26546246.html Tue, 26 May 2026 08:01:36 -0400 GNPX http://www.streetinsider.com/Press+Releases/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html <div class="xn-content"> <p class="prntac"><i>Trop-2 H-scores Above 100 and PTEN H-scores Below 100 Correlated With Longer Progression Free Survival in Non-Small Cell Lung Cancer Patients </i></p><p class="prntac"><i>Identified Biomarkers May Predict Patient Response, Enable Targeted Patient Selection and Allow for Precision Medicine </i></p><p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=3737174704&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex, Inc.</span></a> ("<span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex</span>" or the "Company") (NASDAQ: <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=244160573&amp;u=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2Fgnpx&amp;a=GNPX" target="_blank" rel="nofollow">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators' abstract was published at the http://www.streetinsider.com/Press+Releases/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html Tue, 26 May 2026 08:00:00 -0400 A.06822034 A.40151759 A.42424540 A.50216726 GNPX O.00050368 O.00070991 O.20026344 O.21612337 O.21974237 http://www.streetinsider.com/Press+Releases/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html <div class="xn-content"> <p class="prntac"><i>Trop-2 H-scores Above 100 and PTEN H-scores Below 100 Correlated With Longer Progression Free Survival in Non-Small Cell Lung Cancer Patients </i></p><p class="prntac"><i>Identified Biomarkers May Predict Patient Response, Enable Targeted Patient Selection and Allow for Precision Medicine </i></p><p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=3737174704&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex, Inc.</span></a> ("<span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex</span>" or the "Company") (NASDAQ: <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=244160573&amp;u=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2Fgnpx&amp;a=GNPX" target="_blank" rel="nofollow">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators' abstract was published at the http://www.streetinsider.com/Press+Releases/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html Tue, 26 May 2026 08:00:00 -0400 A.06822034 A.40151759 A.42424540 A.50216726 GNPX O.00050368 O.00070991 O.20026344 O.21612337 O.21974237 http://www.streetinsider.com/Press+Releases/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html <div class="xn-content"> <p class="prntac"><i>Trop-2 H-scores Above 100 and PTEN H-scores Below 100 Correlated With Longer Progression Free Survival in Non-Small Cell Lung Cancer Patients </i></p><p class="prntac"><i>Identified Biomarkers May Predict Patient Response, Enable Targeted Patient Selection and Allow for Precision Medicine </i></p><p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=3737174704&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex, Inc.</span></a> ("<span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex</span>" or the "Company") (NASDAQ: <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=244160573&amp;u=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2Fgnpx&amp;a=GNPX" target="_blank" rel="nofollow">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators' abstract was published at the http://www.streetinsider.com/Press+Releases/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html Tue, 26 May 2026 08:00:00 -0400 A.06822034 A.40151759 A.42424540 A.50216726 GNPX O.00050368 O.00070991 O.20026344 O.21612337 O.21974237 http://www.streetinsider.com/Press+Releases/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html <div class="xn-content"> <p class="prntac"><i>Trop-2 H-scores Above 100 and PTEN H-scores Below 100 Correlated With Longer Progression Free Survival in Non-Small Cell Lung Cancer Patients </i></p><p class="prntac"><i>Identified Biomarkers May Predict Patient Response, Enable Targeted Patient Selection and Allow for Precision Medicine </i></p><p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=3737174704&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex, Inc.</span></a> ("<span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex</span>" or the "Company") (NASDAQ: <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=244160573&amp;u=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2Fgnpx&amp;a=GNPX" target="_blank" rel="nofollow">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators' abstract was published at the http://www.streetinsider.com/Press+Releases/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html Tue, 26 May 2026 08:00:00 -0400 A.06822034 A.40151759 A.42424540 A.50216726 GNPX O.00050368 O.00070991 O.20026344 O.21612337 O.21974237 http://www.streetinsider.com/Press+Releases/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html <div class="xn-content"> <p class="prntac"><i>Trop-2 H-scores Above 100 and PTEN H-scores Below 100 Correlated With Longer Progression Free Survival in Non-Small Cell Lung Cancer Patients </i></p><p class="prntac"><i>Identified Biomarkers May Predict Patient Response, Enable Targeted Patient Selection and Allow for Precision Medicine </i></p><p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=3737174704&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex, Inc.</span></a> ("<span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex</span>" or the "Company") (NASDAQ: <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=244160573&amp;u=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2Fgnpx&amp;a=GNPX" target="_blank" rel="nofollow">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators' abstract was published at the http://www.streetinsider.com/Press+Releases/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html Tue, 26 May 2026 08:00:00 -0400 A.06822034 A.40151759 A.42424540 A.50216726 GNPX O.00050368 O.00070991 O.20026344 O.21612337 O.21974237 http://www.streetinsider.com/Press+Releases/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html <div class="xn-content"> <p class="prntac"><i>Trop-2 H-scores Above 100 and PTEN H-scores Below 100 Correlated With Longer Progression Free Survival in Non-Small Cell Lung Cancer Patients </i></p><p class="prntac"><i>Identified Biomarkers May Predict Patient Response, Enable Targeted Patient Selection and Allow for Precision Medicine </i></p><p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=3737174704&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex, Inc.</span></a> ("<span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex</span>" or the "Company") (NASDAQ: <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=244160573&amp;u=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2Fgnpx&amp;a=GNPX" target="_blank" rel="nofollow">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators' abstract was published at the http://www.streetinsider.com/Press+Releases/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html Tue, 26 May 2026 08:00:00 -0400 A.06822034 A.40151759 A.42424540 A.50216726 GNPX O.00050368 O.00070991 O.20026344 O.21612337 O.21974237 http://www.streetinsider.com/Press+Releases/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html <div class="xn-content"> <p class="prntac"><i>Trop-2 H-scores Above 100 and PTEN H-scores Below 100 Correlated With Longer Progression Free Survival in Non-Small Cell Lung Cancer Patients </i></p><p class="prntac"><i>Identified Biomarkers May Predict Patient Response, Enable Targeted Patient Selection and Allow for Precision Medicine </i></p><p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=3737174704&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex, Inc.</span></a> ("<span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex</span>" or the "Company") (NASDAQ: <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=244160573&amp;u=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2Fgnpx&amp;a=GNPX" target="_blank" rel="nofollow">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators' abstract was published at the http://www.streetinsider.com/Press+Releases/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html Tue, 26 May 2026 08:00:00 -0400 A.06822034 A.40151759 A.42424540 A.50216726 GNPX O.00050368 O.00070991 O.20026344 O.21612337 O.21974237 http://www.streetinsider.com/Press+Releases/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html <div class="xn-content"> <p class="prntac"><i>Trop-2 H-scores Above 100 and PTEN H-scores Below 100 Correlated With Longer Progression Free Survival in Non-Small Cell Lung Cancer Patients </i></p><p class="prntac"><i>Identified Biomarkers May Predict Patient Response, Enable Targeted Patient Selection and Allow for Precision Medicine </i></p><p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=3737174704&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex, Inc.</span></a> ("<span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex</span>" or the "Company") (NASDAQ: <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=244160573&amp;u=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2Fgnpx&amp;a=GNPX" target="_blank" rel="nofollow">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators' abstract was published at the http://www.streetinsider.com/Press+Releases/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html Tue, 26 May 2026 08:00:00 -0400 A.06822034 A.40151759 A.42424540 A.50216726 GNPX O.00050368 O.00070991 O.20026344 O.21612337 O.21974237 http://www.streetinsider.com/Press+Releases/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html <div class="xn-content"> <p class="prntac"><i>Trop-2 H-scores Above 100 and PTEN H-scores Below 100 Correlated With Longer Progression Free Survival in Non-Small Cell Lung Cancer Patients </i></p><p class="prntac"><i>Identified Biomarkers May Predict Patient Response, Enable Targeted Patient Selection and Allow for Precision Medicine </i></p><p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=3737174704&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex, Inc.</span></a> ("<span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex</span>" or the "Company") (NASDAQ: <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=244160573&amp;u=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2Fgnpx&amp;a=GNPX" target="_blank" rel="nofollow">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators' abstract was published at the http://www.streetinsider.com/Press+Releases/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html Tue, 26 May 2026 08:00:00 -0400 A.06822034 A.40151759 A.42424540 A.50216726 GNPX O.00050368 O.00070991 O.20026344 O.21612337 O.21974237 http://www.streetinsider.com/Press+Releases/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html <div class="xn-content"> <p class="prntac"><i>Trop-2 H-scores Above 100 and PTEN H-scores Below 100 Correlated With Longer Progression Free Survival in Non-Small Cell Lung Cancer Patients </i></p><p class="prntac"><i>Identified Biomarkers May Predict Patient Response, Enable Targeted Patient Selection and Allow for Precision Medicine </i></p><p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=3737174704&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex, Inc.</span></a> ("<span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex</span>" or the "Company") (NASDAQ: <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=244160573&amp;u=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2Fgnpx&amp;a=GNPX" target="_blank" rel="nofollow">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators' abstract was published at the http://www.streetinsider.com/Press+Releases/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html Tue, 26 May 2026 08:00:00 -0400 A.06822034 A.40151759 A.42424540 A.50216726 GNPX O.00050368 O.00070991 O.20026344 O.21612337 O.21974237 http://www.streetinsider.com/PRNewswire/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html <div class="xn-content"> <p class="prntac"><i>Trop-2 H-scores Above 100 and PTEN H-scores Below 100 Correlated With Longer Progression Free Survival in Non-Small Cell Lung Cancer Patients </i></p><p class="prntac"><i>Identified Biomarkers May Predict Patient Response, Enable Targeted Patient Selection and Allow for Precision Medicine </i></p><p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=3737174704&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex, Inc.</span></a> ("<span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex</span>" or the "Company") (NASDAQ: <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=244160573&amp;u=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2Fgnpx&amp;a=GNPX" target="_blank" rel="nofollow">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators' abstract was published at the http://www.streetinsider.com/PRNewswire/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html Tue, 26 May 2026 08:00:00 -0400 A.06822034 A.40151759 A.42424540 A.50216726 GNPX O.00050368 O.00070991 O.20026344 O.21612337 O.21974237 http://www.streetinsider.com/PRNewswire/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html <div class="xn-content"> <p class="prntac"><i>Trop-2 H-scores Above 100 and PTEN H-scores Below 100 Correlated With Longer Progression Free Survival in Non-Small Cell Lung Cancer Patients </i></p><p class="prntac"><i>Identified Biomarkers May Predict Patient Response, Enable Targeted Patient Selection and Allow for Precision Medicine </i></p><p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=3737174704&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex, Inc.</span></a> ("<span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex</span>" or the "Company") (NASDAQ: <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=244160573&amp;u=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2Fgnpx&amp;a=GNPX" target="_blank" rel="nofollow">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators' abstract was published at the http://www.streetinsider.com/PRNewswire/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html Tue, 26 May 2026 08:00:00 -0400 A.06822034 A.40151759 A.42424540 A.50216726 GNPX O.00050368 O.00070991 O.20026344 O.21612337 O.21974237 http://www.streetinsider.com/PRNewswire/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html <div class="xn-content"> <p class="prntac"><i>Trop-2 H-scores Above 100 and PTEN H-scores Below 100 Correlated With Longer Progression Free Survival in Non-Small Cell Lung Cancer Patients </i></p><p class="prntac"><i>Identified Biomarkers May Predict Patient Response, Enable Targeted Patient Selection and Allow for Precision Medicine </i></p><p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=3737174704&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex, Inc.</span></a> ("<span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex</span>" or the "Company") (NASDAQ: <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=244160573&amp;u=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2Fgnpx&amp;a=GNPX" target="_blank" rel="nofollow">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators' abstract was published at the http://www.streetinsider.com/PRNewswire/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html Tue, 26 May 2026 08:00:00 -0400 A.06822034 A.40151759 A.42424540 A.50216726 GNPX O.00050368 O.00070991 O.20026344 O.21612337 O.21974237 http://www.streetinsider.com/PRNewswire/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html <div class="xn-content"> <p class="prntac"><i>Trop-2 H-scores Above 100 and PTEN H-scores Below 100 Correlated With Longer Progression Free Survival in Non-Small Cell Lung Cancer Patients </i></p><p class="prntac"><i>Identified Biomarkers May Predict Patient Response, Enable Targeted Patient Selection and Allow for Precision Medicine </i></p><p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=3737174704&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex, Inc.</span></a> ("<span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex</span>" or the "Company") (NASDAQ: <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=244160573&amp;u=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2Fgnpx&amp;a=GNPX" target="_blank" rel="nofollow">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators' abstract was published at the http://www.streetinsider.com/PRNewswire/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html Tue, 26 May 2026 08:00:00 -0400 A.06822034 A.40151759 A.42424540 A.50216726 GNPX O.00050368 O.00070991 O.20026344 O.21612337 O.21974237 http://www.streetinsider.com/PRNewswire/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html <div class="xn-content"> <p class="prntac"><i>Trop-2 H-scores Above 100 and PTEN H-scores Below 100 Correlated With Longer Progression Free Survival in Non-Small Cell Lung Cancer Patients </i></p><p class="prntac"><i>Identified Biomarkers May Predict Patient Response, Enable Targeted Patient Selection and Allow for Precision Medicine </i></p><p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=3737174704&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex, Inc.</span></a> ("<span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex</span>" or the "Company") (NASDAQ: <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=244160573&amp;u=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2Fgnpx&amp;a=GNPX" target="_blank" rel="nofollow">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators' abstract was published at the http://www.streetinsider.com/PRNewswire/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html Tue, 26 May 2026 08:00:00 -0400 A.06822034 A.40151759 A.42424540 A.50216726 GNPX O.00050368 O.00070991 O.20026344 O.21612337 O.21974237 http://www.streetinsider.com/PRNewswire/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html <div class="xn-content"> <p class="prntac"><i>Trop-2 H-scores Above 100 and PTEN H-scores Below 100 Correlated With Longer Progression Free Survival in Non-Small Cell Lung Cancer Patients </i></p><p class="prntac"><i>Identified Biomarkers May Predict Patient Response, Enable Targeted Patient Selection and Allow for Precision Medicine </i></p><p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=3737174704&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex, Inc.</span></a> ("<span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex</span>" or the "Company") (NASDAQ: <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=244160573&amp;u=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2Fgnpx&amp;a=GNPX" target="_blank" rel="nofollow">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators' abstract was published at the http://www.streetinsider.com/PRNewswire/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html Tue, 26 May 2026 08:00:00 -0400 A.06822034 A.40151759 A.42424540 A.50216726 GNPX O.00050368 O.00070991 O.20026344 O.21612337 O.21974237 http://www.streetinsider.com/PRNewswire/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html <div class="xn-content"> <p class="prntac"><i>Trop-2 H-scores Above 100 and PTEN H-scores Below 100 Correlated With Longer Progression Free Survival in Non-Small Cell Lung Cancer Patients </i></p><p class="prntac"><i>Identified Biomarkers May Predict Patient Response, Enable Targeted Patient Selection and Allow for Precision Medicine </i></p><p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=3737174704&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex, Inc.</span></a> ("<span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex</span>" or the "Company") (NASDAQ: <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=244160573&amp;u=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2Fgnpx&amp;a=GNPX" target="_blank" rel="nofollow">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators' abstract was published at the http://www.streetinsider.com/PRNewswire/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html Tue, 26 May 2026 08:00:00 -0400 A.06822034 A.40151759 A.42424540 A.50216726 GNPX O.00050368 O.00070991 O.20026344 O.21612337 O.21974237 http://www.streetinsider.com/PRNewswire/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html <div class="xn-content"> <p class="prntac"><i>Trop-2 H-scores Above 100 and PTEN H-scores Below 100 Correlated With Longer Progression Free Survival in Non-Small Cell Lung Cancer Patients </i></p><p class="prntac"><i>Identified Biomarkers May Predict Patient Response, Enable Targeted Patient Selection and Allow for Precision Medicine </i></p><p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=3737174704&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex, Inc.</span></a> ("<span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex</span>" or the "Company") (NASDAQ: <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=244160573&amp;u=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2Fgnpx&amp;a=GNPX" target="_blank" rel="nofollow">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators' abstract was published at the http://www.streetinsider.com/PRNewswire/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html Tue, 26 May 2026 08:00:00 -0400 A.06822034 A.40151759 A.42424540 A.50216726 GNPX O.00050368 O.00070991 O.20026344 O.21612337 O.21974237 http://www.streetinsider.com/PRNewswire/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html <div class="xn-content"> <p class="prntac"><i>Trop-2 H-scores Above 100 and PTEN H-scores Below 100 Correlated With Longer Progression Free Survival in Non-Small Cell Lung Cancer Patients </i></p><p class="prntac"><i>Identified Biomarkers May Predict Patient Response, Enable Targeted Patient Selection and Allow for Precision Medicine </i></p><p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=3737174704&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex, Inc.</span></a> ("<span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex</span>" or the "Company") (NASDAQ: <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=244160573&amp;u=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2Fgnpx&amp;a=GNPX" target="_blank" rel="nofollow">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators' abstract was published at the http://www.streetinsider.com/PRNewswire/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html Tue, 26 May 2026 08:00:00 -0400 A.06822034 A.40151759 A.42424540 A.50216726 GNPX O.00050368 O.00070991 O.20026344 O.21612337 O.21974237 http://www.streetinsider.com/PRNewswire/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html <div class="xn-content"> <p class="prntac"><i>Trop-2 H-scores Above 100 and PTEN H-scores Below 100 Correlated With Longer Progression Free Survival in Non-Small Cell Lung Cancer Patients </i></p><p class="prntac"><i>Identified Biomarkers May Predict Patient Response, Enable Targeted Patient Selection and Allow for Precision Medicine </i></p><p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=3737174704&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex, Inc.</span></a> ("<span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex</span>" or the "Company") (NASDAQ: <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4695198-1&amp;h=244160573&amp;u=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2Fgnpx&amp;a=GNPX" target="_blank" rel="nofollow">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators' abstract was published at the http://www.streetinsider.com/PRNewswire/Positive+Clinical+Data+on+Biomarkers+in+Patients+Receiving+Reqorsa%C2%AE+Gene+Therapy+Published+at+the+2026+ASCO+Annual+Meeting/26546178.html Tue, 26 May 2026 08:00:00 -0400 A.06822034 A.40151759 A.42424540 A.50216726 GNPX O.00050368 O.00070991 O.20026344 O.21612337 O.21974237 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Genprex%2C+Inc.+++++++++++++For%3A+May+14/26490418.html si-local-file:///var/storage/secattach/20260514/26490418.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Genprex%2C+Inc.+++++++++++++For%3A+May+14/26490418.html Thu, 14 May 2026 08:05:00 -0400 GNPX O.21974237